Dr Philippe Bishop is joining the California-based biopharma firmGilead from Genentech to be the company’s senior vice president of its haematology and oncology therapeutics unit.
Bishop will be reporting to John McHutchison who is the firm’s executive VP for clinical research, and have responsibility for Gilead’s oncology programmes along with joining its executive committee.
Bishop joins Gilead from Genentech where he has served as VP for its product development and oncology wing since 2007. There he was responsible for the development of Avastin and was a member of the Roche/Genentech joint leadership team.
Prior to joining Genentech Bishop led efforts to develop cancer therapies at Johnson & Johnson and Sanofi-Aventis. He has also held positions at the US Food and Drug Administration (FDA) and the National Institutes of Health (NIH).
“Philippe is an accomplished physician with an extensive background in cancer drug development and I am very pleased to welcome him to Gilead,” says McHutchison. “His clinical development expertise, translational focus and strategic leadership will be of great value as we work to advance our growing pipeline of therapies for haematological malignancies and solid tumors.”
Bishop adds: “I am excited to join this dedicated, scientifically-focussed team, which shares my commitment and passion for scientific innovation, and I look forward to working with them to bring new therapeutic options to people living with cancer.”